ArticlePloS one2017
Circulating microRNAs in patients with intracranial aneurysms.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- MicroRNAs in Aneurysmal Subarachnoid Hemorrhage: A Stage-Specific Model Linking Rupture, Vasospasm, and Outcome.Biomedicines · 2026Review
- circ_0103896/miR-432-5p/FTO feedback loop suppresses the formation and progression of intracranial aneurysm.Non-coding RNA research · 2026Article
- Epigenetic mechanisms in aneurysm formation, growth, and rupture: A systematic review.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2025Review
- Molecular Targets for Intracranial Aneurysm Treatment.International journal of molecular sciences · 2025Review
- The Role of miRNA Expression Profiles in Different Biofluids in Aneurysm Rupture.Journal of Korean Neurosurgical Society · 2025Article
- The Role of miRNAs in Aneurysmal Subarachnoid Hemorrhage.Current molecular medicine · 2025Review
- The Role of Epigenetics in Brain Aneurysm and Subarachnoid Hemorrhage: A Comprehensive Review.International journal of molecular sciences · 2024Review
- MiRNAs as potential therapeutic targets and biomarkers for non-traumatic intracerebral hemorrhage.Biomarker research · 2024Review
- The role of MicroRNA as a potential diagnostic and prognostic biomarker for cerebral aneurysms.Neurosciences (Riyadh, Saudi Arabia) · 2023Article
- Effect of circulating miR‑126 levels on intracranial aneurysms and their predictive value for the rupture of aneurysms: A systematic review and meta‑analysis.Experimental and therapeutic medicine · 2023Article
- MicroRNAs' Role in Diagnosis and Treatment of Subarachnoid Hemorrhage.Diseases (Basel, Switzerland) · 2023Review
- Altered MicroRNA Expression in Intracranial Aneurysmal Tissues: Possible Role in TGF-β Signaling Pathway.Cellular and molecular neurobiology · 2022Article
- microRNAs in Subarachnoid Hemorrhage (Review of Literature).Journal of clinical medicine · 2022Review
- Extracellular Vesicles and Their Associated miRNAs as Potential Biomarkers in Intracranial Aneurysm.Frontiers in molecular biosciences · 2022Review
- Circular RNA circLIFR regulates the proliferation, migration, invasion and apoptosis of human vascular smooth muscle cells via the miR-1299/KDR axis.Metabolic brain disease · 2022Article
- MicroRNAs as Biomarkers for Predicting Complications following Aneurysmal Subarachnoid Hemorrhage.International journal of molecular sciences · 2021Review
- Diagnostic and prognostic potential of circulating miRNAs for intracranial aneurysms.Neurosurgical review · 2021Review
- Characterization of Long Non-coding RNA Signatures of Intracranial Aneurysm in Circulating Whole Blood.Molecular diagnosis & therapy · 2020Article
- Identification of a Plasma Microrna Signature as Biomarker of Subaneurysmal Aortic Dilation in Patients with High Cardiovascular Risk.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe compared circulating microRNA (miRNA) levels in plasma of patients with intracranial aneurysms (IA) to those of controls as a first step towards finding potential biomarkers for individuals at high risk of IA development and its subsequent rupture. PATIENTS AND
methodsUsing a PCR array we measured 370 miRNAs in plasma of 15 patients with prior aneurysmal subarachnoid hemorrhage (aSAH), of whom 11 had an additional unruptured IA (UIA), and of 15 controls. MiRNAs with a difference in levels with an absolute fold change (FC) > 1.2 and p<0.01 were further tested using real-time (RT) PCR in an additional independent set of 15 aSAH patients, 15 untreated UIA patients and 15 controls for replication (absolute FC >1.2 and p<0.05). We used receiver operating characteristic (ROC) curves to illustrate the diagnostic potential of these miRNAs.
resultsThree of five miRNAs with a difference in levels in the PCR array study were replicated with miRNA-183-5p decreased in all patients (FC = -2.2, p = 1.7x10-3), miRNA-200a-3p increased in aSAH patients (FC = 1.8, p = 2.8x10-2) and miRNA-let7b-5p decreased in UIA patients (FC = -1.7, p = 1.27x10-3) as compared to controls. In distinguishing aSAH patients from controls, the area under the ROC curve (AUC) was 0.80 (95% confidence interval (95% CI) 0.63-0.97) for miRNA-183-5p, and 0.74 (95% CI 0.55-0.94) for miRNA-200a-3p. In distinguishing untreated UIA patients from controls, AUC was 0.83 (95% CI 0.69-0.98) for miRNA-183-5p and 0.92 (95% CI 0.81-1) for miRNA-let-7b. DISCUSSION/
conclusionsWe identified three specific circulating miRNAs that are able to discriminate between IA patients and controls. Follow-up studies should assess if these miRNAs may be used biomarkers for identifying individuals at high risk of IA development and its subsequent rupture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.